Spero Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Spero Therapeutics

11/08/2023 01:41

* Spero Therapeutics Inc  SPRO.OQ  reported a quarterly
adjusted
loss of 23 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 34 cents per share.
    * Revenue rose 36.3% to $2.72 million from a year ago;
analysts
expected $1.08 million. 
    * Spero Therapeutics Inc's reported EPS for the quarter was
a loss
of 23 cents​.
    * The mean earnings estimate of analysts had risen by
about 12% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Spero Therapeutics Inc shares had held steady so far this
quarter and lost 16.2% so far this year.
    * The company reported a quarterly loss of $11.91 million.
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 11 at 12:41 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.34          -0.23          Beat
 Mar. 31 2023      -0.33          -0.25          Beat
 Dec. 31 2022      0.04           0.55           Beat
 Sep. 30 2022      -0.30          -0.33          Missed